• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Atai Life Sciences N.V. (NQ: ATAI )

    1.190 +0.010 (+0.85%)
    Streaming Delayed Price Updated: 11:35 AM EDT, Sep 25, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 250,368
    Open 1.180
    Bid (Size) 1.190 (8)
    Ask (Size) 1.200 (143)
    Prev. Close 1.180
    Today's Range 1.170 - 1.200
    52wk Range 1.025 - 2.850
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Psychedelic Drug Stocks +6% Last Week Vs. -13% Previous Week
    The psychedelic compound-based drug market is expected to triple over the next few years, creating many winning stocks in the years to come. 
    Via Talk Markets
    MDMA Therapy For PTSD Faces FDA Delay: Are There Other Ways Forward?
    Via Benzinga
    Exposures Product Safety

    Performance

    YTD
    -29.59%
    -29.59%
    1 Month
    -9.16%
    -9.16%
    3 Month
    -11.85%
    -11.85%
    6 Month
    -31.21%
    -31.21%
    1 Year
    -7.03%
    -7.03%

    More News

    Read More
    Psychedelic Compound-Based Drug Stocks Portfolio -13% W/e Sept. 6th
    Via Talk Markets
    Our Psychedelic Compound-Based Clinical-Stage Drug Stocks Portfolio Was Down 16% In August
    Via Talk Markets
    Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration
    Via Benzinga
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
    From atai Life Sciences
    Via GlobeNewswire
    Largest Psychedelic Compound -Based Clinical-Stage Drug Stocks Up 6% Last Week
    Via Talk Markets
    Psychedelic Compound-Based Drug Stocks Portfolio: Up 17.5% In July; Down 19% MTD
    Via Talk Markets
    Atai's DMT Depression Drug Shows Promise, Prepares For Phase II Trial And Future Collaboration With Pharma Giant
    Via Benzinga
    ATAI Stock Earnings: ATAI Life Sciences Misses EPS for Q2 2024
    Via InvestorPlace
    atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
    From atai Life Sciences
    Via GlobeNewswire
    atai Life Sciences Announces Positive Preliminary Results from Phase 1b Trial of VLS-01 (Buccal Film DMT)
    From atai Life Sciences
    Via GlobeNewswire
    atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference
    From atai Life Sciences
    Via GlobeNewswire
    EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves
    Via Benzinga
    Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD
    Via Talk Markets
    3 Dirt-Cheap Drug Developers With Blockbuster Potential
    Via InvestorPlace
    3 Next-Gen Drug Stocks Exploring Psychedelic Frontiers
    Via InvestorPlace
    3 Psychedelic Stocks to Ride to the Moon and Beyond
    Via InvestorPlace
    Exposures Product Safety
    Psychedelic Picks: 3 Trippy Stocks Aiming for Out-of-This-World Returns
    Via InvestorPlace
    3 Psychedelic Stocks to Buy on the Dip: Summer 2024
    Via InvestorPlace
    Clinical-Stage BioTech Drug Stocks Declined 13% In June
    Via Talk Markets
    atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference
    From atai Life Sciences
    Via GlobeNewswire
    Largest Clinical-Stage BioTech Drug Stocks Declined 6%
    Via Talk Markets
    atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a
    From atai Life Sciences
    Via GlobeNewswire
    Largest Psychedelic Compound Based Drug Stocks Fell 13% Last Week - Here's Why
    Via Talk Markets
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.